Bridging the Idea Development Evaluation Assessment and Long-Term Initiative and Total Product Life Cycle Approaches for Evidence Development for Surgical Medical Devices and Procedures; Public Workshop; Correction, 72423 [2011-30145]

Download as PDF sroberts on DSK5SPTVN1PROD with NOTICES Federal Register / Vol. 76, No. 226 / Wednesday, November 23, 2011 / Notices Contact Person: Caryn Cohen, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 1–(877) 287–1373 (choose option 4), email: TPSAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–(800) 741–8138 ((301) 443–0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting. Agenda: As part of the Tobacco Products Scientific Advisory Committee’s required report to the Secretary of Health and Human Services, the committee will continue discussing issues related to the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children. Discussion will include such topics as the composition and characteristics of dissolvable tobacco products, product use, potential health effects, and marketing. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee link. Procedure: On January 18, 2012, from 2 p.m. to 5 p.m., on January 19, 2012, from 8 a.m. to 5 p.m., and on January 20, 2012 from 8 a.m. to 4 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before January 4, 2012. Oral presentations from the public will be scheduled between approximately 3 p.m. and 4 p.m. on January 19, 2012. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the VerDate Mar<15>2010 17:03 Nov 22, 2011 Jkt 226001 evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before December 27, 2011. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by December 28, 2011. Closed Committee Deliberations: On January 18, 2012, from 8 a.m. to 1 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)). This portion of the meeting must be closed because the Committee will be discussing trade secret and/or confidential data regarding products provided by the tobacco companies. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Caryn Cohen at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: November 16, 2011. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. [FR Doc. 2011–30163 Filed 11–22–11; 8:45 am] BILLING CODE 4160–01–P PO 00000 72423 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2011–N–0780] Bridging the Idea Development Evaluation Assessment and LongTerm Initiative and Total Product Life Cycle Approaches for Evidence Development for Surgical Medical Devices and Procedures; Public Workshop; Correction AGENCY: Food and Drug Administration, HHS. Notice of public workshop; correction. ACTION: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of Monday, November 7, 2011 (76 FR 68769). The document announced a public workshop entitled ‘‘Bridging the Idea Development Evaluation Assessment and Long-Term Initiative and Total Product Life Cycle Approaches for Evidence Development for Surgical Medical Devices and Procedures.’’ The document was published with an incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, Silver Spring, MD 20993–0002, (301) 796–9148. SUPPLEMENTARY INFORMATION: In FR Doc. 2011–28722, appearing on page 68769, in the Federal Register of Monday, November 7, 2011, the following correction is made: On page 68769, in the first column, in the Docket No. heading, ‘‘[Docket No. FDA 2011–N–0002]’’ is corrected to read ‘‘[Docket No. FDA–2011–N–0780]’’. SUMMARY: Dated: November 17, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011–30145 Filed 11–22–11; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\23NON1.SGM 23NON1

Agencies

[Federal Register Volume 76, Number 226 (Wednesday, November 23, 2011)]
[Notices]
[Page 72423]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-30145]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0780]


Bridging the Idea Development Evaluation Assessment and Long-Term 
Initiative and Total Product Life Cycle Approaches for Evidence 
Development for Surgical Medical Devices and Procedures; Public 
Workshop; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of Monday, November 7, 2011 (76 
FR 68769). The document announced a public workshop entitled ``Bridging 
the Idea Development Evaluation Assessment and Long-Term Initiative and 
Total Product Life Cycle Approaches for Evidence Development for 
Surgical Medical Devices and Procedures.'' The document was published 
with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food 
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, 
Silver Spring, MD 20993-0002, (301) 796-9148.

SUPPLEMENTARY INFORMATION: In FR Doc. 2011-28722, appearing on page 
68769, in the Federal Register of Monday, November 7, 2011, the 
following correction is made:
    On page 68769, in the first column, in the Docket No. heading, 
``[Docket No. FDA 2011-N-0002]'' is corrected to read ``[Docket No. 
FDA-2011-N-0780]''.

    Dated: November 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-30145 Filed 11-22-11; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.